LKLeonid Kogan

Leonid Kogan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leonid Kogan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aerobic Cutibacterium acnes/Staphylococcus epidermidis Dual-Species Biofilms: Matrix Components In Vitro and Promotion of Cutibacterium acnes Growth on Human Skin Ex Vivo

    by Jeffrey B. Kaplan, Wisal Sawaed, Amit Zeev Katz, Roman Rysin, Leonid Kogan, Holger Rohde, Khalaf Kridin

    Anaerobic Cutibacterium species and facultatively anaerobic coagulase-negative staphylococci (CoNS) are numerically abundant members of the human skin microbiota. Cutibacterium acnes can form biofilms under aerobic conditions when co-cultured with CoNS, a process that may facilitate its colonization of skin. Here, we characterized aerobic dual-species biofilms formed by C. acnes and CoNS in vitro. Aerobic growth of C. acnes in co-culture with CoNS occurred across multiple phylogenetically diverse C. acnes isolates. Moreover, C. acnes outcompeted CoNS, accounting for >90% of recovered CFUs after 5 d of aerobic co-culture. Mechanical disruption experiments showed that CoNS biofilms were readily detached by vortex agitation, whereas efficient detachment of C. acnes required sonication, suggesting stronger association with the biofilm matrix and/or culture vessel surface. All tested C. acnes strains produced detectable extracellular DNA (eDNA) and poly-N-acetylglucosamine (PNAG), and both components contributed to biofilm structural integrity and biocide resistance in aerobic dual-species biofilms. Finally, S. epidermidis supported aerobic growth of C. acnes on human skin explants ex vivo. These findings provide mechanistic insight into the ability of C. acnes to persist and dominate aerobic polymicrobial biofilms, identify eDNA and PNAG as potential targets for biofilm disruption, and suggest that cooperation with CoNS may facilitate C. acnes colonization and persistence on human skin.

  • Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial

    by Saher Hamed, Yehuda Ullmann, Mark Belokopytov, Aziz Shoufani, Hoda Kabha, Suher Masri, Muhamad Safadi, Zeev Feldbrin, Leonid Kogan, Danny Kruchevsky, et al.

    The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests that topical erythropoietin (EPO) can promote wound healing. The aim of this study is to clinically assess the efficacy of a proprietary topical EPO-containing hydrogel for treating DFUs. We conducted a randomized, controlled trial in 20 patients with DFUs. After a 14-day screening period, the DFUs of 20 eligible participants who fulfilled the inclusion criteria were randomly assigned (1:1) to either a 12-week of daily treatment with topical EPO and standard-of-care (SOC) or SOC treatment alone. The DFUs were assessed weekly until week 12. The primary outcome was 75% ulcer closure or higher. After 12 weeks of treatment, 75% ulcer closure was achieved in 6 of the 10 patients whose DFUs were treated with topical EPO and in one of the 8 patients whose DFUs were treated with SOC alone. The mean area of the DFUs that were treated with topical EPO and SOC was significantly smaller than those treated with SOC alone (1.2 ± 1.4 cm 2 vs. 4.2 ± 3.4 cm 2 ; p = 0.023). Re-epithelialization was faster in the topically EPO-treated DFUs than in the SOC-treated DFUs. There were no treatment-related adverse events. We conclude that topical EPO is a promising treatment for promoting the healing of DFUs. Clinical Trial Registration number: NCT02361931.